Short Interest in Agenus Inc. (NASDAQ:AGEN) Decreases By 8.8%

Agenus Inc. (NASDAQ:AGEN) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,180,000 shares, a decline of 8.8% from the July 15th total of 2,390,000 shares. Currently, 10.9% of the shares of the company are sold short. Based on an average daily volume of 799,300 shares, the short-interest ratio is presently 2.7 days.

Agenus Stock Down 3.6 %

Agenus stock opened at $5.09 on Tuesday. Agenus has a 52-week low of $4.41 and a 52-week high of $31.20. The firm has a market capitalization of $106.88 million, a price-to-earnings ratio of -0.40 and a beta of 1.33. The company has a fifty day simple moving average of $10.89 and a 200-day simple moving average of $11.71.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The firm had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same period last year, the firm earned ($4.00) earnings per share. On average, research analysts anticipate that Agenus will post -10.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

A number of large investors have recently modified their holdings of the business. Powell Investment Advisors LLC acquired a new position in shares of Agenus during the 4th quarter valued at about $166,000. Los Angeles Capital Management LLC boosted its position in shares of Agenus by 95.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 200,812 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 97,992 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Agenus during the 4th quarter valued at about $95,000. RPO LLC acquired a new position in shares of Agenus during the 4th quarter valued at about $43,000. Finally, Crestline Management LP boosted its position in shares of Agenus by 6.5% during the 4th quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock valued at $587,000 after acquiring an additional 43,480 shares during the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on AGEN. HC Wainwright lowered shares of Agenus from a “buy” rating to a “neutral” rating and cut their price target for the stock from $40.00 to $9.00 in a report on Thursday, July 18th. B. Riley cut their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. William Blair lowered shares of Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Finally, Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.